SwedenBIO driving public opinion for Swedish life science and innovation

We are stepping up our efforts to drive opinion on current issues and raise the profile of Swedish life science.

With several ongoing regulatory processes with the potential to affect the conditions for the life science industry, SwedenBIO is focusing on stepping up its advocacy work. At the beginning of the year, we participated in the debate and appeared in the media to draw attention to issues that are important to our members and to highlight the success of Swedish life science.

Opinion piece in Altinget: Sweden’s position as a research nation is under threat

On March 26, we published a joint opinion piece in Altinget together with Lif – the researching pharmaceutical companies, IKEM and Swedish Medtech with a concrete call to the government: “Give a mandate in the upcoming research and innovation bill for an R&I program for life science, with the industry perspective as a guiding star in the design of the program.”

The text highlights a concrete and recent example of how funding for outstanding life science research in collaboration between industry and academia is completely lacking in the government program Impact Innovation. The program is described as “Sweden’s major innovation initiative for the 2030s”, and is run by the Swedish Energy Agency, Formas and Vinnova, but does not cover innovation-driven research in life science.

Read the article here.

Opinion article in SvD – “Don’t reduce our strong pharmaceutical exports”

On March 6, SvD Debatt published the opinion text “Sänk inte vår starka läkemedelsexport” signed by SwedenBIO together with Lif and IKEM. In the text, we make a direct call to the decision makers: “We urge the government and Swedish politicians in the EU to make their voice heard and take an active and driving role in the upcoming negotiations on the new European pharmaceutical legislation that secures our competitiveness and strengthens our attractiveness and competitiveness against other regions.”

Read the article here.

Press release on government statement on EU legislation

On March 11, in a press release, we welcomed the government’s published statement on the proposed changes to data protection in the EU’s draft pharma legislative package. Our announcement was followed up by the Swedish Pharmaceutical Association, among others.

Read the press release here.

SwedenBIO joins government reference group

In parallel with our advocacy and work to raise the profile of Swedish life science, we are proud of the opportunity to speak directly to decision makers at national level. In March, the government announced the establishment of a reference group for life sciences with various representatives of the industry and other stakeholders. SwedenBIO is one of the industry representatives chosen to be part of the group.

– I look forward to a powerful group that comes up with concrete proposals on what the industry needs to succeed internationally,” says Jessica Martinsson, CEO of SwedenBIO about being part of the advisory body.

Highlight and comment on the development of Swedish life science.

Figures from Statistics Sweden (SCB) on Swedish exports from 2023 show that Sweden’s pharmaceutical exports have continued to grow and reach new record levels. SwedenBIO has highlighted the export successes in a press release to the international press.

We have also commented on health data legislation from a Swedish perspective in Euractiv, given our view on the development of license agreements in Biostock and more.